REFERENCES

1. Zhang H, Zhou XD, Shapiro MD, et al. Global burden of metabolic diseases, 1990-2021. Metabolism. 2024;160:155999.

2. Rui L. Energy metabolism in the liver. In: Terjung R, Editor. Comprehensive physiology. Wiley; 2011. pp. 177-97.

3. Karpińska M, Czauderna M. Pancreas-its functions, disorders, and physiological impact on the mammals’ organism. Front Physiol. 2022;13:807632.

4. Silva PH, Mohebbi N. Kidney metabolism and acid-base control: back to the basics. Pflugers Arch. 2022;474:919-34.

5. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98:2133-223.

6. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? Ann Surg. 1995;222:339-50.

7. Hoyt JA, Cozzi E, D’Alessio DA, Thompson CC, Aroda VR. A look at duodenal mucosal resurfacing: rationale for targeting the duodenum in type 2 diabetes. Diabetes Obes Metab. 2024;26:2017-28.

8. Rønnestad I, Akiba Y, Kaji I, Kaunitz JD. Duodenal luminal nutrient sensing. Curr Opin Pharmacol. 2014;19:67-75.

9. Cherrington AD, Rajagopalan H, Maggs D, Devière J. Hydrothermal duodenal mucosal resurfacing: role in the treatment of metabolic disease. Gastrointest Endosc Clin N Am. 2017;27:299-311.

10. Rajagopalan H, Cherrington AD, Thompson CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39:2254-61.

11. Weiskirchen R, Lonardo A. How ‘miracle’ weight-loss semaglutide promises to change medicine but can we afford the expense? Br J Pharmacol. 2025;182:1651-70.

12. Lim GE, Brubaker PL. Glucagon-like peptide 1 secretion by the L-cell: the view from within. Diabetes. 2006;55:S70-7.

13. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-39.

14. Mayo Clinic. Ablation therapy. Available from https://www.mayoclinic.org/tests-procedures/ablation-therapy/about/pac-20385072 [accessed 18 March 2025].

15. West JA, Tsakmaki A, Huang JHS, et al. Proximal and distal gut mucosa adapt differently to westernized diet, promoting an insulin-resistant dysmetabolic state. bioRχiv 2019; bioRχiv:2019.

16. Chiu HHC, Wang JS. Potential of duodenal mucosal resurfacing in achieving glycemic control in Asians with type 2 diabetes. Ther Adv Endocrinol Metab. 2024;15:20420188241252308.

17. Gong EJ, Kim DH. Small bowel endoscopic bariatric therapies. Clin Endosc. 2018;51:425-9.

18. Meiring S, Busch CBE, van Baar ACG, et al. Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events. Cardiovasc Diabetol. 2022;21:191.

19. Simons M, Sharaiha RZ. Updates in metabolic bariatric endoscopy. Dig Endosc. 2024;36:107-15.

20. van Baar ACG, Beuers U, Wong K, et al. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. JHEP Rep. 2019;1:429-37.

21. van Baar ACG, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 2020;69:295-303.

22. van Baar ACG, Meiring S, Smeele P, et al. Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study. Gastrointest Endosc. 2021;94:111-20.e3.

23. Hadefi A, Verset L, Pezzullo M, et al. Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study. Endosc Int Open. 2021;9:E1792-800.

24. van Baar ACG, Devière J, Hopkins D, et al. Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study). Diabetes Res Clin Pract. 2022;184:109194.

25. Meiring S, van Baar ACG, Sørensen N, et al. A changed gut microbiota diversity is associated with metabolic improvements after duodenal mucosal resurfacing with glucagon-like-peptide-1 receptor agonist in type 2 diabetes in a pilot study. Front Clin Diabetes Healthc. 2022;3:856661.

26. Meiring S, Meessen ECE, van Baar ACG, et al. Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes. Am J Physiol Endocrinol Metab. 2022;322:E132-40.

27. Mingrone G, van Baar AC, Devière J, et al; Investigators of the REVITA-2 Study. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. 2022;71:254-64.

28. Chuang TJ, Ko CW, Shiu SI. The metabolic influence of duodenal mucosal resurfacing for nonalcoholic fatty liver disease. Medicine. 2023;102:e35147.

29. Fonseca V, Bergman J, Saeed ZI, et al. 824-P: glycemic improvement, insulin reductions, and improved body weight 48 weeks after revita duodenal mucosal resurfacing in t2d patients with previously inadequately controlled glucose despite multiple glucose-lowering agents including insulin. Diabetes. 2023;72:824P.

30. Busch CBE, Meiring S, van Baar ACG, et al. Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot study. Gastrointest Endosc. 2024;100:473-80.e1.

31. Musso G, Pinach S, Saba F, De Michieli F, Cassader M, Gambino R. Endoscopic duodenal mucosa ablation techniques for diabetes and nonalcoholic fatty liver disease: a systematic review. Med. 2024;5:75-58.e2.

32. Falcetta P, Nicolì F, Citro F, et al. De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes. Acta Diabetol. 2023;60:53-60.

33. Nunes G, Guimarães M, Coelho H, et al. Prolonged fasting induces histological and ultrastructural changes in the intestinal mucosa that may reduce absorption and revert after enteral refeeding. Nutrients. 2023;16:128.

34. Aliluev A, Tritschler S, Sterr M, et al. Diet-induced alteration of intestinal stem cell function underlies obesity and prediabetes in mice. Nat Metab. 2021;3:1202-16.

35. Mussa BM, Sood S, Verberne AJ. Implication of neurohormonal-coupled mechanisms of gastric emptying and pancreatic secretory function in diabetic gastroparesis. World J Gastroenterol. 2018;24:3821-33.

36. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130.

37. Pillon NJ, Loos RJF, Marshall SM, Zierath JR. Metabolic consequences of obesity and type 2 diabetes: balancing genes and environment for personalized care. Cell. 2021;184:1530-44.

38. Telese A, Sehgal V, Magee CG, et al. Bariatric and metabolic endoscopy: a new paradigm. Clin Transl Gastroenterol. 2021;12:e00364.

39. Nie L, Yan Q, Zhang S, Cao Y, Zhou X. Duodenal mucosa: a new target for the treatment of type 2 diabetes. Endocr Pract. 2023;29:53-9.

40. Rajagopalan H, Lopez-Talavera JC, Klonoff DC, Cherrington AD. A gut-centric model of metabolic homeostasis. J Diabetes Sci Technol. 2022;16:1567-74.

41. Hadefi A, Arvanitakis M, Huberty V, Devière J. Metabolic endoscopy: today’s science-tomorrow’s treatment. United European Gastroenterol J. 2020;8:685-94.

42. Ghusn W, Calderon G, Abu Dayyeh BK, Acosta A. Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity. Clin Endosc. 2024;57:701-10.

43. Matteo MV, Bove V, Pontecorvi V, et al. The evolution and current state of bariatric endoscopy in Western countries. Clin Endosc. 2024;57:711-24.

44. De Luca M, Shikora S, Eisenberg D, et al. Scientific evidence for the updated guidelines on indications for metabolic and bariatric surgery (IFSO/ASMBS). Surg Obes Relat Dis. 2024;20:991-1025.

45. Jastreboff AM, le Roux CW, Stefanski A, et al; SURMOUNT-1 Investigators. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958-71.

46. Nathan DM, Lachin JM, Bebu I, et al; GRADE Study Research Group. Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes. N Engl J Med. 2022;387:1075-88.

47. Yang H, Hu B. Duodenal mucosal resurfacing before its use in clinical practice. Gastrointest Endosc. 2022;96:875.

48. Cottam A, Cottam D, Roslin M, Surve A. Exploring bariatric surgery’s impact on weight loss and diabetes: sodium and glucose receptor modulation. JSLS. 2024;28:e2023.00051.

49. Busch CBE, Meiring S, van Baar ACG, Holleman F, Nieuwdorp M, Bergman JJGHM. Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human study. Gastrointest Endosc. 2024;100:896-904.